Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

7.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
7.6K
Tumor Progression02:07

Tumor Progression

6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Multimodal Artificial Intelligence Model to Guide Use of Whole-Pelvic Radiation Therapy in Patients with Localized Prostate Cancer: Exploratory Analysis of RTOG 9413.

Cancers·2026
Same author

Association Between Cribriform Architecture and Tertiary Gleason Pattern 5 in Prostate Cancer: A Cross-Sectional Study of Radical Prostatectomy Specimens.

Journal of clinical medicine·2026
Same author

Clinical perspectives on pediatric weight-management programs: A nationwide look at models of care.

Obesity pillars·2026
Same author

An Interferon-Response Transcriptomic Signature of Lymphovascular Invasion in Prostate Cancer.

International journal of molecular sciences·2026
Same author

Association Between Cribriform Architecture and Lymphovascular Invasion in Prostate Cancer.

Journal of clinical medicine·2026
Same author

Prophylactic Cranial Irradiation in Small Cell Lung Cancer: Evolution of Evidence, Current Status, and Future Directions.

Current issues in molecular biology·2026

Related Experiment Video

Updated: May 6, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.7K

Transcriptomic Profile of Perineural Invasion in Prostate Cancer Identifies Prognostic Gene Signatures.

Cagdas Aktan1, Swati Mamidanna2, Caryn Cobb3

  • 1Department of Medical Biology, Faculty of Medicine, Bandirma Onyedi, Eylul University, Balikesir 10250, Türkiye.

Biomedicines
|August 28, 2025
PubMed
Summary
This summary is machine-generated.

Genomic alterations in prostate cancer linked to perineural invasion (PNI) may predict disease progression. Identifying these genetic markers, such as AZGP1, ASPN, COMP, RYR2, and SFRP4, can help assess post-prostatectomy risk.

Keywords:
perineural invasionprognostic biomarkersprostate cancer

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.9K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K

Related Experiment Videos

Last Updated: May 6, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.7K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.9K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K

Area of Science:

  • Oncology
  • Genomics
  • Prostate Cancer Research

Background:

  • Prostate cancer is a prevalent male malignancy with diverse histopathologic features impacting prognosis.
  • Perineural invasion (PNI) is a recognized indicator of aggressive prostate cancer.
  • Understanding genomic alterations associated with PNI is crucial for predicting disease behavior.

Purpose of the Study:

  • To investigate genomic alterations associated with perineural invasion (PNI) in prostate cancer patients.
  • To identify specific genes whose expression levels correlate with PNI status and patient survival.
  • To evaluate the prognostic significance of these identified genomic alterations following radical prostatectomy.

Main Methods:

  • Retrospective analysis of 421 prostate cancer patients from The Cancer Genome Atlas who underwent radical prostatectomy.
  • Identification of differentially expressed genes between patients with and without perineural invasion (PNI).
  • Analysis of mRNA expression levels of key genes and their correlation with disease-free survival using statistical models.

Main Results:

  • Significantly higher mRNA expression of COL9A3, ASPN, ESR1, MUC1, PIP, SFRP4, KRT19, CLDN1, and COMP in tumors with PNI.
  • Elevated expression of RYR2, MME, and AZGP1 observed in tumors without PNI.
  • High AZGP1 expression correlated with longer disease-free survival; high ASPN, COMP, RYR2, and SFRP4 expression correlated with shorter survival.

Conclusions:

  • Genomic alterations associated with PNI in prostate cancer may indicate an elevated risk of post-prostatectomy progression.
  • Specific gene expression profiles can serve as potential biomarkers for predicting disease recurrence.
  • Further prospective studies are warranted to validate these genomic findings and their clinical implications.